-$0.44 Earnings Per Share Expected for Benitec Biopharma Inc. (NASDAQ:BNTC) This Quarter

Wall Street analysts expect that Benitec Biopharma Inc. (NASDAQ:BNTCGet Rating) will announce earnings per share (EPS) of ($0.44) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Benitec Biopharma’s earnings. Benitec Biopharma posted earnings per share of ($164.69) during the same quarter last year, which indicates a positive year-over-year growth rate of 99.7%. The company is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Benitec Biopharma will report full-year earnings of ($2.08) per share for the current fiscal year. For the next financial year, analysts anticipate that the business will report earnings of ($1.34) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Benitec Biopharma.

Benitec Biopharma (NASDAQ:BNTCGet Rating) last announced its quarterly earnings results on Monday, February 14th. The biotechnology company reported ($117.99) earnings per share for the quarter. The business had revenue of $0.03 million for the quarter.

Separately, HC Wainwright assumed coverage on shares of Benitec Biopharma in a research note on Thursday, February 17th. They issued a “buy” rating and a $10.00 price target on the stock.

Shares of BNTC opened at $1.36 on Wednesday. The company has a quick ratio of 5.11, a current ratio of 5.11 and a debt-to-equity ratio of 0.06. Benitec Biopharma has a twelve month low of $1.26 and a twelve month high of $5.86. The firm’s 50 day moving average price is $2.02 and its two-hundred day moving average price is $2.62.

A hedge fund recently raised its stake in Benitec Biopharma stock. Geode Capital Management LLC lifted its holdings in Benitec Biopharma Inc. (NASDAQ:BNTCGet Rating) by 8.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,413 shares of the biotechnology company’s stock after purchasing an additional 4,721 shares during the quarter. Geode Capital Management LLC owned 0.71% of Benitec Biopharma worth $153,000 as of its most recent SEC filing. Institutional investors and hedge funds own 21.00% of the company’s stock.

About Benitec Biopharma (Get Rating)

Benitec Biopharma Inc, a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection.

Featured Stories

Get a free copy of the Zacks research report on Benitec Biopharma (BNTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.